LIMN Stock Forecast: Liminatus Pharma, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 10 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Liminatus Pharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (45): Reported profit is backed by cash, and the company is not expanding recklessly.
Volatility (8): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
LIMN stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on LIMN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
LIMN appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
LIMN vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Liminatus Pharma, Inc. returned −95.1% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
LIMN analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 9.3×
- EV / EBITDA
- —
Cheaper than 8% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- —
- Return on assets
- −95.7%
- Dividend yield
- —
Higher than 3% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Liminatus Pharma, Inc. has a market value of $3.4M and an enterprise value of $1.8M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$12.5M.
Free cash flow in the twelve months to 30 June 2026: −$4.0M.
Liminatus Pharma, Inc. employs 1 people.
Data provided by Twelve Data
LIMN and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at LIMN’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Liminatus Pharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about LIMN
How does Ticker Nerd's model rank LIMN?
As at 21 Nov 2026, Liminatus Pharma, Inc. ranks 10 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (45 of 100).
What is the LIMN stock forecast for 2030?
No analyst covering Liminatus Pharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LIMN are extrapolating price history, which says nothing about the business.
How has LIMN stock performed over the past year?
Liminatus Pharma, Inc. returned -95.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Liminatus Pharma, Inc. do?
Liminatus Pharma, Inc. is a pre-clinical-stage biopharmaceutical company focused on developing immuno-oncology therapies for cancer. The company’s current work centers on immune-modulating treatments designed to address solid tumors, with a particular emphasis on CD47-blockade technology and its candidate IBA101, a humanized anti-CD47 monoclonal antibody.
About Liminatus Pharma, Inc.
Liminatus Pharma, Inc. is a pre-clinical-stage biopharmaceutical company focused on developing immuno-oncology therapies for cancer. The company’s current work centers on immune-modulating treatments designed to address solid tumors, with a particular emphasis on CD47-blockade technology and its candidate IBA101, a humanized anti-CD47 monoclonal antibody. Liminatus Pharma is also associated with broader oncology research efforts that explore next-generation immune-based approaches and CAR-T platforms for difficult-to-treat cancers. Its business is concentrated in the biotechnology and healthcare sectors, where it contributes to the development of targeted cancer therapies intended to expand treatment options in oncology. Founded in 2018 and headquartered in California, Liminatus Pharma remains focused on advancing clinical research and therapeutic development for patients with unmet needs in cancer care.
CEO Mr. Chris Kim J.D., L.L.M. · 1 employees · United States · https://liminatuspharma.com